CymaBay Therapeutics, Inc.
CBAYNASDAQHealthcare
$32.48
+$0.01(+0.03%)
Market Cap$3.7B
P/E Ratio—
52W High$32.5
52W Low$7.261
CymaBay Therapeutics, Inc. (CBAY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CBAY · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $31.07M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $0.68M | $0.71M | $0.69M | $0.63M | $0.80M |
| Gross Profit | $30.39M | ($0.71M) | ($0.69M) | ($0.63M) | ($0.80M) |
| Gross Margin %(computed) | 97.81% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $80.12M | $68.00M | $64.54M | $35.88M | $83.84M |
| G&A Expenses | $51.95M | $25.12M | $23.04M | $17.43M | $19.24M |
| Total Operating Expenses | $132.07M | $93.11M | $87.58M | $53.31M | $103.08M |
| Operating Income | ($101.68M) | ($93.11M) | ($87.58M) | ($52.60M) | ($108.15M) |
| Operating Margin %(computed) | -327.23% | — | — | — | — |
| Interest Income | $13.49M | $2.02M | $0.17M | $1.62M | $5.34M |
| Interest Expense | $18.95M | $14.91M | $2.58M | $0.00M | $0.00M |
| Income Before Tax | ($105.37M) | ($106.00M) | ($90.00M) | ($50.99M) | ($102.81M) |
| Income Tax Expense | $0.00M | $12.89M | $2.58M | ($2.32M) | ($0.57M) |
| Net Income | ($105.37M) | ($118.89M) | ($92.58M) | ($48.66M) | ($102.24M) |
| Net Margin %(computed) | -339.10% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.99 | $-1.35 | $-1.30 | $-0.71 | $-1.53 |
| Wtd Avg Shares | 106.20M | 87.80M | 71.06M | 68.89M | 67.03M |
| EBITDA | ($85.74M) | ($92.40M) | ($86.73M) | ($50.35M) | ($108.15M) |
| EBITDA Margin %(computed) | -275.94% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more CymaBay Therapeutics, Inc. data
About CymaBay Therapeutics, Inc. (CBAY) Income Statement
CymaBay Therapeutics, Inc. (CBAY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, CBAY reported revenue of $0.03B, gross profit of $0.03B (gross margin 97.81%), and net income of ($0.11B) — a net profit margin of -339.10%.
Frequently asked questions
CBAY · 4 questionsCymaBay Therapeutics, Inc. (CBAY) reported revenue of $0.03B for 2023, up —% year-over-year.
CBAY revenueCBAY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08